R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

NCT01446900 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

OTHER

Sponsor class

Stopped low rate in patient accrual

Conditions

Chronic Lymphocytic Leukaemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Rituximab
DRUG: Cladribine

Sponsor

European Institute of Oncology